ZBIO
Zenas Biopharma, Inc.
A clinical-stage biopharmaceutical company developing therapies for autoimmune diseases. Its lead candidate, obexelimab, is a bifunctional antibody that calms overactive B cells without destroying them, and it met its primary goal in a late-stage trial for the rare condition IgG4-related disease. Founded in 2020 by serial entrepreneur Lonnie Moulder, the company takes its name from the ancient Greek "Zenas," meaning "gift of Zeus."
CUSIP: 98937L105HealthcareUS2 holders
Total Value
$36.13M
Total Shares
995.0K
Net Share Change
-73.5K
Activity
1 selling
Investor
Value
Shares
Weight
Change
